Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes

Pillai, Ashwin A.; Sharma, Ashish M.; Krayem, Hussein; Frishman, William H.; Aronow, Wilbert S.

doi:10.1097/crd.0000000000001139

Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes

The therapeutic landscape for obesity and type 2 diabetes mellitus (T2DM) is being reshaped by glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Orforglipron (LY3502970) represents a significant evolution in this class. Given the limitations of injectable GLP-1 RAs and the administration con…